N. Clumeck

M. Goldman, B. Byl, N. Clumeck, 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Corticosteroids as adjunctive therapy for Pneumocystis pneumonia in patients with AIDS.

P. Meier, H. Masur, J. McCutchan, 1991, The New England journal of medicine.

The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV‐1 RNA copies/mL at baseline

N. Clumeck, A. Hill, M. Nelson, 2012, HIV medicine.

Current problems in the management of AIDS patients

N. Clumeck, S. Wit, P. Hermans, 1988, European Journal of Clinical Microbiology and Infectious Diseases.

Heterosexual Contact Is Not the Predominant Mode of HTLV-III Transmission Among Intravenous Drug Abusers-Reply

N. Clumeck, 1986 .

Dynamics of SARS-CoV-2 RT-PCR positivity and seroprevalence among high-risk healthcare workers and hospital staff

N. Clumeck, S. De Wit, O. Vandenberg, 2020, Journal of Hospital Infection.

Single cell analysis of antigen-specific T cell responses in HIV-infected individuals.

F. Mascart, M. Goldman, B. Byl, 1999, Cellular immunology.

HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico

N. Volkow, K. Tashima, D. Podzamczer, 2016, Journal of the International AIDS Society.

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

A. Horban, N. Clumeck, G. Fätkenheuer, 2010, AIDS.

SMALL INTRAVENOUS INSULIN BOLUSES IN THE TREATMENT OF DIABETIC COMA

R. Naeije, E. Balasse, N. Clumeck, 1975, The Lancet.

started? When should antiretroviral therapy for HIV be

A. Phillips, J. Lundgren, N. Clumeck, 2007 .

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

R. Haubrich, M. Kozal, K. Tashima, 2014, The Journal of infectious diseases.

Use of hydroxyurea in heavily pretreated patients with HIV infection.

N. Clumeck, P. Hermans, S. D. de Wit, 1999, Antiviral therapy.

Gag-specific CD4+ T-cell responses are associated with virological control of paediatric HIV-1 infection

P. Goulder, N. Clumeck, S. De Wit, 2011, AIDS.

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline.

A. Rieger, N. Clumeck, J. Arribas, 2011, The Journal of antimicrobial chemotherapy.

Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials

P. Cahn, N. Clumeck, J. Molina, 2010, International journal of STD & AIDS.

Salmonella bacteremia in African patients with human immunodeficiency virus infection

H. Taelman, N. Clumeck, P. Perre, 1988, European Journal of Clinical Microbiology and Infectious Diseases.

Cerebral Toxoplasmosis over the last 10 years in a 2394 patient cohort in Brussels

N. Clumeck, S. Wit, Á. Baráth, 2000 .

TRIZAL study: switching from successful HAART to TrizivirTM (abacavir‐lamivudine‐zidovudine combination tablet): 48 weeks efficacy, safety and adherence results

B. Gazzard, C. Katlama, A. Lazzarin, 2003, HIV medicine.

Immunological aspects of severe bacterial sepsis

N. Clumeck, C. George, 1981, Intensive Care Medicine.

Recombinant granulocyte colony-stimulating factor (rG-CSF) in HIV patients with zidovudine related neutropenia.

N. Clumeck, S. Wit, P. Hermans, 1992, Journal of nutritional science and vitaminology.

Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study

T. Griffin, R. Dewar, J. Metcalf, 2017, Open forum infectious diseases.

Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.

B. Clotet, C. Katlama, N. Clumeck, 2010, The Journal of antimicrobial chemotherapy.

[Septicaemia and spontaneous peritonitis in the cirrhotic (author's transl)].

M. Estenne, N. Clumeck, R. Vanhoof, 1979, La Nouvelle presse medicale.

Maraviroc for previously treated patients with R5 HIV-1 infection.

Anders Karlsson, Edwin DeJesus, Bonaventura Clotet, 2008, The New England journal of medicine.

Mutations in HIV-1 Reverse Transcriptase during Therapy with Abacavir, Lamivudine and Zidovudine in HIV-1-Infected Adults with No Prior Antiretroviral Therapy

M. Fischl, N. Clumeck, M. Ait-Khaled, 2002, Antiviral therapy.

Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study

N. Clumeck, S. De Wit, N. Dauby, 2011, Journal of the International AIDS Society.

Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015

R. Schooley, E. Maltezos, Tak-chiu Wu, 2017, Open forum infectious diseases.

Baseline factors prognostic of sustained virological response in patients with HIV–hepatitis C virus co-infection

C. Tural, D. Cooper, D. Dieterich, 2007, AIDS.

Risk factors of osteopenia in HIV-infected women: no role of antiretroviral therapy.

K. Kabeya, N. Clumeck, M. Tondeur, 2010, Maturitas.

Human immunodeficiency virus transmission among heterosexual couples in Central Africa.

S. Allen, N. Clumeck, P. Lepage, 1988, AIDS.

STIMULATION OF CELLULAR FUNCTION BY THYMOPENTIN (TP-5) IN THREE AIDS PATIENTS

N. Clumeck, K. Huygen, K. Bolla, 1983, The Lancet.

Treatment of Toxoplasmic Encephalitis in Patients with AIDS

N Clumeck, J. McCutchan, B. Luft, 1992, Annals of Internal Medicine.

Fungal infections in the AIDS patient

N. Clumeck, S. Wit, 1991 .

Safety and Efficacy of Single-Dose Fluconazole Compared with a 7-Day Regimen of Itraconazole in the Treatment of AIDS-Related Oropharyngeal Candidiasis

C. de Vroey, N. Clumeck, S. De Wit, 1998, The Journal of international medical research.

Fluconazole in the treatment of fungal infections associated with AIDS

N. Clumeck, S. Wit, 1989, Infection.

FLUCONAZOLE VERSUS KETOCONAZOLE IN OROPHARYNGEAL CANDIDIASIS IN AIDS

N. Clumeck, D. Smith, B. Gazzard, 1989, The Lancet.

Efficacy of oral fluconazole in the treatment of AIDS associated oesophageal candidiasis

N. Clumeck, D. Weerts, S. Wit, 1991, European Journal of Clinical Microbiology and Infectious Diseases.

Cefotaxime therapy of serious infections with multiresistant gram-negative bacilli.

N. Clumeck, J. Butzler, Y. Van Laethem, 1982, Scandinavian journal of infectious diseases.

Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms

N. Clumeck, J. Butzler, Y. Van Laethem, 1983, Antimicrobial Agents and Chemotherapy.

A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome in Africa.

J. Bogaerts, N. Clumeck, D. Rouvroy, 1985, American journal of ophthalmology.

A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS.

N. Clumeck, M. Payen, S. D. de Wit, 1997, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS.

C. Katlama, N. Clumeck, S. Wit, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.

J. Falloon, H. Masur, S. Bozzette, 1993, The New England journal of medicine.

Indicator disease‐guided testing for HIV – the next step for Europe?

B. Gazzard, A. d’Arminio Monforte, J. Lundgren, 2008, HIV medicine.

Single-dose versus 7 days of fluconazole treatment for oral candidiasis in human immunodeficiency virus-infected patients: a prospective, randomized pilot study.

H. Goossens, N. Clumeck, S. de Wit, 1993, The Journal of infectious diseases.

Treatment of HIV‐related fluconazole‐resistant oral candidosis with D0870, a new triazole antifungal

B. Gazzard, D. Hawkins, D. Denning, 1998, AIDS.

A dose comparison study of a new triazole antifungal (D0870) in HIV‐positive patients with oral candidiasis

B. Gazzard, D. Hawkins, D. Denning, 1997, AIDS.

Amoxicillin Entry into Human Cerebrospinal Fluid: Comparison with Ampicillin

N. Clumeck, J. Butzler, J. Thys, 1978, Antimicrobial Agents and Chemotherapy.

Pancreatic disturbances and typhoid fever.

N. Clumeck, Y. Van Laethem, S. D. de Wit, 1991, Scandinavian journal of infectious diseases.

Anticardiolipin antibodies (ACA) are most often not associated with lupus‐like anticoagulant (LLAC) in human immunodeficiency virus (HIV) infection

A. Janssens, N. Clumeck, D. Vandevelde, 1991, American journal of hematology.

A controlled trial of zidovudine in primary human immunodeficiency virus infection.

D. Hawkins, J. Saurat, T. Perneger, 1995, The New England journal of medicine.

FEMALE PROSTITUTES: A RISK GROUP FOR INFECTION WITH HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE III

M. Robert-Guroff, N. Clumeck, J. Butzler, 1985, The Lancet.

Pilot study of a new triazole derivative (D0870) in HIV patients with oral candidiasis

B. Gazzard, D. Hawkins, D. Denning, 1994 .

HIV and Syphilis: When to Perform a Lumbar Puncture

E. Negredo, J. Gatell, N. Clumeck, 2007, Sexually transmitted diseases.

Effect of Fluconazole on Indinavir Pharmacokinetics in Human Immunodeficiency Virus-Infected Patients

P. Deutsch, N. Clumeck, S. De Wit, 1998, Antimicrobial Agents and Chemotherapy.

Therapeutic approach to mycotic infections in AIDS patients

N. Clumeck, S. Wit, 1991 .

Pharmacokinetics of two multiple dosing regimens of D0870 in HIV positive patients: a phase I study

N. Clumeck, R. Yates, S. Wit, 1995 .

Bovine leukemia virus-related antigens in lymphocyte cultures infected with AIDS-associated viruses.

A. Burny, N. Clumeck, D. Portetelle, 1985, Science.

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients : A randomized controlled comparison with zidovudine monotherapy

C. Katlama, S. Staszewski, M. Johnson, 1996 .

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.

Giorgio Palù, Simon Collins, Rodolphe Thiebaut, 2005, Journal of hepatology.

Update on highly active antiretroviral therapy: progress and strategies.

N. Clumeck, S. D. de Wit, 2000, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

A randomized study investigating the efficacy and safety of amprenavir in combination with low‐dose ritonavir in protease inhibitor‐experienced HIV‐infected adults

C. Katlama, N. Clumeck, F. Pulido, 2004, HIV medicine.

The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex. The European-Australian Collaborative Group.

C. Farthing, D. Cooper, N. Clumeck, 1991, AIDS (London).

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

C. Katlama, S. Staszewski, C. Loveday, 1996, JAMA.

Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing

JD Lundgren, N Clumeck, A. D. Luca, 2004, Antiviral therapy.

Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue.

E. De Clercq, M. Van Ranst, N. Clumeck, 1995, The New England journal of medicine.

A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.

R. Schooley, R. Haubrich, D. Richman, 1999, AIDS.

Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-finding study of oral administration compared with intravenous infusion

N. Clumeck, S. De Wit, P. Hermans, 1992, Antimicrobial Agents and Chemotherapy.

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

M. Moroni, F. Antunes, J. Montaner, 2003, AIDS.

Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.

Z. Fox, P. Vernazza, M. Youle, 2003, The Journal of infectious diseases.

Corrigendum to “SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS”[J Hepatol 42 (2005) 615–624]

P. Reiss, J. Lundgren, Y. Yazdanpanah, 2005 .

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study

JD Lundgren, N Clumeck, A. Mocroft, 2007, The Lancet.

Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients

N. Clumeck, S. De Wit, J. Schmit, 2004, AIDS.

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

Huldrych F. Günthard, Tulio de Oliveira, Lynn Morris, 2016 .

Effect of Baseline CD4 Cell Count on the Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Patients With HIV/Hepatitis C Virus Coinfection

J. Montaner, B. Clotet, D. Cooper, 2008, Journal of acquired immune deficiency syndromes.

Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.

F. Antunes, C. Katlama, A. Lazzarin, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Randomized Trial to Evaluate Continuation versus Discontinuation of Lamivudine in Individuals Failing A Lamivudine-Containing Regimen: The Colate Trial

Z. Fox, C. Katlama, A. Phillips, 2005, Antiviral therapy.

The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group.

M. Moroni, É. Oksenhendler, B. Hirschel, 1993, AIDS.

A new topical treatment for resistant herpes simplex infections.

E. De Clercq, N. Clumeck, G. Andrei, 1993, The New England journal of medicine.

Treatment of a bowenoid papulosis of the penis with local applications of cidofovir in a patient with acquired immunodeficiency syndrome.

E. De Clercq, N. Clumeck, Y. Van Laethem, 2001, Archives of internal medicine.

Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less: week 48 phase III analysis

N. Clumeck, J. Molina, L. Rimsky, 2013, AIDS.

Week 96 analysis of rilpivirine or efavirenz in HIV‐1‐infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double‐blind trials

C. Orkin, N. Clumeck, J. Molina, 2014, HIV medicine.

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

S. Walmsley, N. Clumeck, B. Wynne, 2013, The New England journal of medicine.

Efficacy and tolerability of the combination of Lopinavir/Ritonavir and Amprenavir in patients with multiple protease inhibitors resistant HIV strains: results at week 24

K. Kabeya, N. Clumeck, S. Wit, 2001 .

Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection

W. Rozenbaum, N. Clumeck, F. Castelli, 1996, AIDS.

Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.

Z. Fox, J. Lundgren, P. Cahn, 2007, Basic & clinical pharmacology & toxicology.

AIDS and associated cancers in Africa.

N. Clumeck, G. Giraldo, E. Beth‐giraldo, 1988 .

The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003

A. Mocroft, O. Kirk, F. Antunes, 2004, Cancer.

Serum sensitivity of strains isolated and antibodies against O antigen in gram-negative bacteraemia.

Y. Englert, N. Clumeck, J. Butzler, 1982, Scandinavian journal of infectious diseases.

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression

Arsène Burny, Anna Kula, J. Gatot, 2015, PLoS pathogens.

Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.

R. Weber, L. Perrin, D. Cooper, 2000, The Journal of infectious diseases.

Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma

G. Zissis, P. Lacor, N. Clumeck, 1996, Journal of clinical microbiology.

Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patients

J. Gatot, C. Van Lint, C. Rouzioux, 2012, AIDS.

Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results.

N. Clumeck, Y. Van Laethem, P. Hermans, 1988, The Journal of antimicrobial chemotherapy.

Sequential treatment with 5‐aza‐2′‐deoxycytidine and deacetylase inhibitors reactivates HIV‐1

Anna Kula, J. Gatot, C. Van Lint, 2015, EMBO molecular medicine.

Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection

Arsène Burny, Dolores Vaira, J. Gatot, 2009, PloS one.

Publications - Division of Infectious Diseases & Hospital Epidemology 2005

B. Reboussin, P. Reiss, J. Lundgren, 2005 .

Treatment of acute toxoplasmosis with intravenous clindamycin

J. McCutchan, B. Luft, P. Morlat, 1991, European Journal of Clinical Microbiology and Infectious Diseases.

Treatment of severe staphylococcal infections with a rifampicin-minocycline association.

N. Clumeck, B. Gordts, L. Marcelis, 1984, The Journal of antimicrobial chemotherapy.

A LOW T3 SYNDROME IN DIABETIC KETOACIDOSIS

L. Vanhaelst, R. Naeije, N. Clumeck, 1978, Clinical endocrinology.

The role of excess iron in the pathogenesis of disturbed neutrophil functions in cirrhotic patients (neutrophil functions in cirrhotic patients).

P. Magrez, N. Clumeck, Y. Van Laethem, 1987, Acta clinica Belgica.

Rapid diagnosis of bacterial meningitis.

N. Clumeck, S. Lauwers, 1981, The Journal of infection.

Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006.

Anne-Mieke Vandamme, Katrien Fransen, Inge Derdelinckx, 2008, AIDS research and human retroviruses.

Seroepidemiological studies of HTLV-III antibody prevalence among selected groups of heterosexual Africans.

M. Robert-Guroff, R. Gallo, N. Clumeck, 1985, JAMA.

Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance.

Soriano, K. Hertogs, F. Brun-Vézinet, 2001, AIDS.

European guidelines for the clinical management and treatment of HIV-infected adults in Europe.

V. Soriano, M. Youle, P. Reiss, 2003, AIDS.

Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen

F. Antunes, B. Clotet, L. Ruiz, 2007, AIDS.

Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study

R. Shafer, P. Kaleebu, D. Pillay, 2016, The Lancet. Infectious diseases.

Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death

A. Mocroft, O. Kirk, A. Blaxhult, 2007, HIV medicine.

Indinavir/ritonavir‐based therapy in HIV‐1‐infected antiretroviral therapy‐naive patients: comparison of 800/100 mg and 400/100 mg twice daily

A. Huitema, N. Clumeck, D. Konopnicki, 2005, HIV medicine.

Relationship between current level of immunodeficiency and non‐acquired immunodeficiency syndrome‐defining malignancies

A. Mocroft, O. Kirk, F. Antunes, 2010, Cancer.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

Karin J. Metzner, Huldrych F. Günthard, E. Nicastri, 2014, The Journal of antimicrobial chemotherapy.

Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. The AIDS IN EUROPE Study Group.

A. Phillips, A. Lazzarin, J. Lundgren, 1996, Journal of clinical epidemiology.

Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter

J. Gatell, D. Cooper, F. Goebel, 1993 .

Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study)

Stefan Esser, Josip Begovac, Jens D. Lundgren, 2013, PloS one.

STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS *

P. Reiss, J. Lundgren, Y. Yazdanpanah, 2005 .

Preliminary results on clinical and immunological effects of thymus hormone preparations in AIDS

N. Clumeck, P. Hermans, 1989, Medical oncology and tumor pharmacotherapy.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

AFRICAN SWINE FEVER VIRUS ANTIBODY NOT FOUND IN AIDS PATIENTS

N. Clumeck, J. Goudsmit, J. Colaert, 1983, The Lancet.

Cytomegalovirus retinitis in patients with AIDS in Europe

C. Katlama, J. Gatell, B. Ledergerber, 1997, European Journal of Clinical Microbiology and Infectious Diseases.

Neutropenia in patients with HIV infection: a case control study in a cohort of 1403 patients between 1982 and 1993.

N. Clumeck, P. Hermans, B. Sommereijns, 1999, Journal of hematotherapy & stem cell research.

Minimum effective dose and duration to reverse neutropenia in non-cancer patients with advanced HIV disease.

N. Clumeck, P. Hermans, S. Gray, 1996, AIDS.

Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study

A. Grzeszczuk, M. L. Jakobsen, J. Minton, 2015, PloS one.

Recently diagnosed sexually HIV-infected patients: seroconversion interval, partner notification period and a high yield of HIV diagnoses among partners.

R. French, S. Bird, N. Clumeck, 2001, QJM : monthly journal of the Association of Physicians.

10 Fox

Z. Fox, C. Katlama, A. Phillips, 2006 .

Comparison of Metabolic Abnormalities and Clinical Lipodystrophy 48 Weeks After Switching from HAART to Trizivir™ Versus Continued HAART: The Trizal Study

M. Johnson, J. Mallolas, N. Clumeck, 2003, HIV clinical trials.

CD4 response to monotherapy with stavudine in zidovudine experienced patients: lack of correlation of V75T mutation with therapeutical failure

N. Clumeck, S. Wit, A. Papadopoulos, 1996 .

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

Bonaventura Clotet, A. LaMarca, B. Clotet, 2012, The Lancet. Infectious diseases.

Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study.

D. Dieterich, N. Clumeck, P. Buggisch, 2008, Journal of hepatology.

Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine

Anne M Johnson, Andrew N. Phillips, Reggio Emilia, 1994 .

Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. AIDS in Europe Study Group.

C. Katlama, J. Lundgren, N. Clumeck, 1996, AIDS.

Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group.

J. Nielsen, J. Gatell, A. Phillips, 1994, JAMA.

Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group.

J. Nielsen, C. Katlama, J. Gatell, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Feasibility and acceptability of HIV screening through the use of rapid tests by general practitioners in a Brussels area with a substantial African community

N. Clumeck, A. Gennotte, C. Necsoi, 2013, HIV medicine.

Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?

B. Gazzard, A. Mocroft, O. Kirk, 2008, AIDS.

A perspective of the history of HAART

N. Clumeck, D. Konopnicki, 2004 .

Choosing the best initial therapy for HIV-1 infection.

N. Clumeck, 1999, The New England journal of medicine.

A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.

Anne M Johnson, Jens D. Lundgren, Anders Blaxhult, 1999, Journal of acquired immune deficiency syndromes.

Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140)

K. Kabeya, N. Clumeck, L. Curtis, 2007, Antimicrobial Agents and Chemotherapy.

The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe.

M. Johnson, M. Opravil, N. Clumeck, 2000 .

Jesse Green, N. Wintfeld, C. Cohen, 2004, Journal of acquired immune deficiency syndromes.

Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis [Case study].

N. Clumeck, S. De Wit, Y. Van Laethem, 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Acquired resistance to clarithromycin as combined therapy in Mycobacterium avium intracellulare infection

N. Clumeck, P. Mol, S. Wit, 1993, The Lancet.

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

D. Cooper, Naitee Ting, M. Saag, 2010, The Journal of infectious diseases.

Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.

J. Montaner, E. Seminari, J. Gatell, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ritonavir/Saquinavir plus One Nucleoside Reverse Transcriptase Inhibitor (NRTI) versus Indinavir plus Two Nrtis in Protease Inhibitor-Naive HIV-1-Infected Adults (Iris Study)

C. Dreezen, N. Clumeck, E. Smets, 2000, Antiviral therapy.

Sweet's syndrome in an HIV-infected patient.

N. Clumeck, Y. Van Laethem, P. Hermans, 1999, AIDS.

THYROID HORMONES IN SERIOUS NON-THYROIDAL ILLNESS

G. Somers, L. Vanhaelst, R. Naeije, 1976, The Lancet.

Clinical and pharmacological evaluation of different preparations of oral erythromycin.

N. Clumeck, J. Butzler, P. de Mol, 1979, Chemotherapy.

HPV and HIV coinfection: a complex interaction resulting in epidemiological, clinical and therapeutic implications

N. Clumeck, D. Konopnicki, S. Wit, 2013 .

Efficacy and Safety of Trazodone versus Clorazepate in the Treatment of HIV-Positive Subjects with Adjustment Disorders: A Pilot Study

N. Clumeck, S. De Wit, D. Hirsch, 1999, The Journal of international medical research.

R. Gallo, Y. Lunardi-Iskandar, N. Clumeck, 1998, Journal of human virology.

Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis.

N. Clumeck, S. De Wit, Y. Van Laethem, 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Pattern of HIV heterosexual infection in Brussels

P. Magrez, N. Clumeck, S. Wit, 1988 .

Rising Prevalence of HIV-1 Non-B Subtypes in Belgium: 1983–2001

A. Vandamme, K. Van Laethem, J. Snoeck, 2004, Journal of acquired immune deficiency syndromes.

Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.

Ravindra K. Gupta, N. Clumeck, A. Hill, 2013, The Journal of infectious diseases.

, of Aplaviroc ( GW 873140 ) Hepatotoxicity Observed in Clinical Trials

K. Kabeya, N. Clumeck, L. Curtis, 2008 .

[Professional fatigue syndrome (burnout) : Part 2 : from therapeutic management].

N. Clumeck, W. Pitchot, A. Massart, 2017, Revue Medicale de Liege.

Double-blind randomized study of oral Fluconazole versus Ketoconazole in 40 episodes of oropharyngeal cadidiasis in ARC/AIDS patients

N. Clumeck, D. Weerts, S. Wit, 1989 .

Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system.

A. Vandamme, G. Zissis, K. Van Laethem, 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

A Dose-Ranging Study to Evaluate the Antiretroviral Activity and Safety of Amprenavir Alone and in Combination with Abacavir in HIV-Infected Adults with Limited Antiretroviral Experience

R. Schooley, R. Haubrich, F. Antunes, 2000, Antiviral Therapy.

Kaposi's sarcoma in patients infected with human virus (HIV): an overview.

N. Clumeck, P. Hermans, 1995, Cellular and molecular biology.

Effects of switching to protease inhibitor monotherapy on nucleoside analogue-related adverse events.

N. Clumeck, A. Hill, C. Moecklinghoff, 2014, AIDS reviews.

VIRUS-LIKE PARTICLES IN LYMPHOCYTES OF SEVEN CASES OF AIDS IN BLACK AFRICANS

N. Clumeck, W. Feremans, P. Dustin, 1983, The Lancet.

Histological response to pegIFNα-2a (40KD) plus ribavirin in HIV–hepatitis C virus co-infection

J. Montaner, D. Dieterich, N. Clumeck, 2006, AIDS.

Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases.

N. Clumeck, S. De Wit, O. Vandenberg, 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic

Henrik Nielsen, L. Mathiesen, C. Leen, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.

B. Gazzard, J. Montaner, R. Weber, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

94 – Opportunistic Infections: Management and Prevention

N. Clumeck, S. Wit, 2017 .

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.

Tania B. Huedo-Medina, M. Hughes, P. Sax, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.

Philip R. Johnson, S. Kochhar, J. van Lunzen, 2008, AIDS research and human retroviruses.

LAV/HTLV-III infection in children of African origin: Experience in Belgium

H. Taelman, G. Zissis, N. Clumeck, 1986, European Journal of Pediatrics.